Gonadorelin is a synthetic copy of gonadotropin-releasing hormone (GnRH), the brain signal that tells the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).1 Those two hormones drive testosterone production and sperm production in the testes. An FDA-approved human gonadorelin product existed but is no longer manufactured.2 Testosterone therapy (TRT) suppresses LH, FSH and sperm production,3 which is why men on TRT ask about gonadorelin. If fertility or testicular function matters to you, your physician can plan for it before you start.
How GnRH Signals the Testes
GnRH is made in the hypothalamus and acts on the anterior pituitary. Gonadorelin has the same amino acid sequence as the body's own GnRH, so it sends the same signal.1 The effect on the testes is indirect, because gonadorelin works only through the hormones the pituitary releases in response.
The LH and FSH Signal
LH drives testosterone production inside the testes. FSH supports sperm production. When your pituitary releases both, your testes make testosterone locally and keep producing sperm. When both fall, as they do on TRT, intratesticular testosterone drops sharply and sperm production slows.3
That chain explains the interest in gonadorelin. It also means gonadorelin depends on a working pituitary. If your pituitary cannot respond, gonadorelin cannot raise LH and FSH, and your physician will look at other options.
Pulse Timing and the Pituitary Response
The body releases GnRH in pulses, and the pituitary responds to the pattern. In monkeys with hypothalamic lesions that stopped gonadotropin release, hourly pulses of synthetic GnRH restored LH and FSH secretion. A constant infusion failed to restore it.4 Switching those animals from pulses to continuous delivery could desensitize the pituitary's gonadotropin release.4
For you, the practical point is that delivery timing changes the effect of a GnRH signal. How a GnRH product is given is a prescribing decision with consequences, and your prescriber sets it.
Human Fertility Evidence for Pulsatile Gonadorelin
The human evidence for gonadorelin comes from men with hypogonadotropic hypogonadism (HH), a condition in which the brain or pituitary does not send enough LH and FSH. The studies of gonadorelin itself used a pump that delivers it in pulses.
Sperm Production in Congenital HH
Zhang L et al. followed 28 men with congenital HH and no sperm in their semen.5 Ten used a pulsatile gonadorelin pump, and 18 used cyclical injections of the gonadotropins hCG and hMG. Sperm appeared sooner on the pump, at a median of 6 months compared with 14 months. By the end of the study, sperm production had started in 90% of the pump group and 83.3% of the gonadotropin group, and the authors found no statistical difference between the two rates.5 Allergic skin redness was a common side effect of the pump.5
The study was not randomized and was small. Its result gives your physician a reference point for men with HH, and for men on TRT your physician draws on studies of men taking testosterone.3
Pooled Results Across Studies
A meta-analysis by Rastrelli G et al. pooled 16 studies of GnRH therapy and 44 of gonadotropin therapy in men with HH and azoospermia.6 Both approaches produced sperm in about 75% of men.6 GnRH therapy and gonadotropins therefore look similar on this outcome in this population.
Bone and Metabolic Changes
In 22 young men with HH, six months of pulsatile gonadorelin was followed by higher bone mineral density at the spine and hip. Total cholesterol, fasting insulin, insulin resistance and sex hormone-binding globulin (SHBG) fell.7 With no treated comparison group, the study shows change over six months of treatment, and those are markers your physician can read on your own panel.
Where Testicular Function Fits on TRT
TRT gives your body testosterone from outside, so the pituitary lowers LH and FSH. Naelitz BD et al. describe the result: endogenous testosterone production falls, intratesticular testosterone drops sharply and spermatogenesis is impaired.3 Sperm production often returns after TRT stops, but the speed of recovery varies widely, which can complicate family planning.3
The Endocrine Society recommends against starting testosterone therapy in men planning fertility in the near term.8 Naelitz BD et al. go further and call exogenous testosterone contraindicated in men trying to conceive.3 If you want children, that is a conversation to have before you start TRT.
For men who are on TRT and want to protect sperm production, the 2025 review lists aromatase inhibitors, selective estrogen receptor antagonists, hCG and FSH as examples of therapies used in select patients.3 The gonadorelin fertility studies enrolled men with HH. They did not enroll men on TRT, so their results do not transfer directly to gonadorelin used alongside testosterone. Your physician weighs that gap against your goals. If keeping your own production running is the main goal, TRT vs enclomiphene, enclomiphene and Clomid for men cover options that raise LH and FSH instead of replacing testosterone.
Regulatory History and Current Supply
Gonadorelin was approved by the FDA as a human drug, and that product is no longer manufactured.2 The gonadorelin labels currently listed on DailyMed come from animal-health companies. Factrel, for example, is approved by the FDA for use in cattle, and its label reads "Not for human use."1
Gonadorelin prescribed for a man today is therefore not an FDA-approved human product. Vasylieva V et al. advise clinicians to separate approved therapies from investigational and nonregulated compounds, and to counsel patients on uncertain benefit and the risks of unsupervised use.2 If gonadorelin is part of your plan, you can ask your prescriber which pharmacy prepares it and how its quality is checked.
A Prescriber's Questions Before Gonadorelin
A physician considering gonadorelin for you works through these questions first:
- Your diagnosis. Primary hypogonadism starts in the testes, while secondary hypogonadism starts in the brain or pituitary. The hypogonadism page explains the difference, and the Endocrine Society recommends finding the cause.8
- Your fertility timeline. Children soon, children later or no plans changes which options make sense.3,8
- Your baseline. Total and free testosterone, LH, FSH, estradiol and a semen analysis set the starting point. What a low sperm count means explains that last test.
- The evidence gap. The gonadorelin data come from men with HH on a pump, which your physician weighs against options studied on TRT.3,5,6
- The follow-up plan. Testosterone, hematocrit and symptoms are monitored on any testosterone plan.8
The dose and schedule are set by your prescriber from those answers. The testosterone therapy page covers the TRT side of the decision.
The Opt Take on Gonadorelin
A gonadorelin decision rests on two questions: where any low testosterone starts, in the testes or the pituitary, and whether you want to keep your own production running. Your labs answer the first. Your plans answer the second. One testosterone number cannot answer either. The pattern across LH, FSH and testosterone tells your physician where the problem starts.
At Opt Health, you start with a panel of 55+ biomarkers, then a 1:1 review with an Opt Health physician who sets your plan from the results. That plan can include prescriptions shipped from our pharmacy to your home. Full labs and a physician consultation repeat every 3 to 4 months, so the plan is adjusted on what your numbers did.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Gonadorelin is synthetic GnRH with the same amino acid sequence as the hormone your hypothalamus makes.1 It signals the pituitary to release LH and FSH. The FDA-approved human product is no longer manufactured, and the labeled products on DailyMed are veterinary.1,2 If you are offered it, ask your prescriber where it is made.
Gonadorelin binds GnRH receptors on the pituitary, which then releases LH and FSH.1 LH drives testosterone production in the testes, and FSH supports sperm production. The pituitary responds to pulses: in monkeys, hourly pulses restored LH and FSH while a constant infusion did not.4 How it is given changes what it does in you, so your prescriber sets that part.
In men with hypogonadotropic hypogonadism, pulsatile gonadorelin started sperm production in 90% of a small study group.5 GnRH therapy produced sperm in about 75% of men across 16 pooled studies.6 Those men were not on TRT. If you are on TRT, your physician weighs this evidence alongside options studied in your situation.3
It works in the population studied. In men with HH, pulsatile gonadorelin produced sperm at rates similar to gonadotropin injections.5,6 Whether it preserves testicular function in men taking TRT has not been shown in those studies, because they did not enroll men on TRT. Your physician can tell you which option has the best evidence for your goal.
Vasylieva V et al. record that gonadorelin was FDA approved and is no longer manufactured.2 The review's summary gives no reason for the discontinuation. For you, the practical fact is that any gonadorelin prescribed today is not that approved human product, so ask your prescriber how it is sourced.1,2
In men with congenital HH using a pulsatile pump, sperm first appeared at a median of 6 months.5 Gonadotropin injections took a median of 14 months in the same study.5 That timeline applies to men with HH starting from no sperm. The gonadorelin studies did not measure how fast gonadorelin works in men on TRT, so if you are on TRT, your physician tracks your own response with repeat testing.
A fertility plan starts with knowing where your hormone pattern begins. An Opt Health membership pairs 55+ biomarkers with a 1:1 physician review, then repeats labs and a physician consultation every 3 to 4 months.
References
- Zoetis Inc. Factrel (gonadorelin hydrochloride) injection [label]. DailyMed. Updated September 29, 2026. Accessed October 14, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1451663c-b85a-4b45-8b27-6d572d0032f9
- Vasylieva V, et al. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev. 2026;14(4). https://pubmed.ncbi.nlm.nih.gov/42862021/
- Naelitz BD, et al. Testosterone replacement therapy and spermatogenesis in reproductive age men. Nat Rev Urol. 2025;22(10):703-719. https://pubmed.ncbi.nlm.nih.gov/40346275/
- Belchetz PE, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631-633. https://pubmed.ncbi.nlm.nih.gov/100883/
- Zhang L, et al. The pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men. Am J Mens Health. 2019;13(1):1557988318818280. https://pubmed.ncbi.nlm.nih.gov/30569789/
- Rastrelli G, et al. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology. 2014;2(6):794-808. https://pubmed.ncbi.nlm.nih.gov/25271205/
- Li CX, et al. Changes in bone mineral density and metabolic parameters after pulsatile gonadorelin treatment in young men with hypogonadotropic hypogonadism. Int J Endocrinol. 2015;2015:324524. https://pubmed.ncbi.nlm.nih.gov/26417369/
- Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
This article is part of our guide to testosterone. See how physician-managed TRT works at Opt Health.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.